poisar

Stocks · News reference

Neuphoria Therapeutics Q4 EPS $(0.95) Misses $(0.56) Estimate, Sales $1.174M.

Benzinga Newsdesk

Neuphoria Therapeutics (NASDAQ:NEUP) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of $(0.56) by 69.64 percent. This is a 76.13 percent increase over losses of $(3.98) per

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

NEUP
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGAR

    8-K filing — Neuphoria Therapeutics Inc. (NEUP)

    Filed: 2026-10-23 AccNo: 0001213900-26-111863 Size: 216 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.03: Material Modifications to Rights of Security Holders Item 9.01: Financial Statements and Exhibits

    NEUP